Blow For Novartis Eye Drug Beovu As Studies Stop On Safety Worries

Intraocular Inflammation Cases Higher Than Rival

The Swiss giant Novartis has decided to halt the MERLIN, RAVEN and RAPTOR studies of Beovu "in the interests of patient safety" which will make the task of competing with the wet AMD market leader Eylea even tougher.

Eye
• Source: Archive

The rollercoaster ride for Novartis AG’s eye drug Beovu has continued following further safety concerns leading to the termination of a key study in wet age-related macular degeneration (AMD) despite the therapy hitting its efficacy goals when compared with Bayer AG and Regeneron Pharmaceuticals, Inc.'s market-leading rival anti-VEGF therapy Eylea.

The Swiss major reported the first year results of the two-year Phase III MERLIN study assessing Beovu (brolucizumab) 6mg versus...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Sensory

More from Therapeutic Category